Characterization of Mycoplasma pneumoniae Infection and Outcomes in the SOLITAIRE-Oral, Global Phase 3 Clinical Trial for Solithromycin
Abstract
Background: Solithromycin is a 4th generation macrolide antibiotic with potent activity against typical and atypical pathogens that cause community acquired bacterial pneumonia (CABP), including ‘macrolide-resistant’ pneumococci and Mycoplasma pneumoniae (Mpn). In SOLITAIRE-Oral, a global Phase 3 clinical trial, a 5-day course of oral solithromycin was demonstrated to be non-inferior to a 7-day course of oral moxifloxacin for treatment of community acquired bacterial pneumonia (CABP) among adult patients with PORT II-IV disease.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.